CRAVES FRED B 4

Accession 0001628280-25-012826

CIK 0001157601other

View on SEC.gov Company Profile

Filed

Mar 13, 8:00 PM ET

Accepted

Mar 14, 4:25 PM ET

Size

37.3 KB

Accession

0001628280-25-012826

Insider Transaction Report

Form 4

Period: 2025-03-12

MADRIGAL PHARMACEUTICALS, INC.MDGL

CRAVES FRED B

Director

Transactions

Sale
Common Stock
2025-03-12$332.38/sh−2,382$791,726→ 351,076 total
Sale
Common Stock
2025-03-12$334.97/sh−200$66,994→ 350,076 total
Sale
Common Stock
2025-03-13$328.68/sh−400$131,472→ 351,118 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-03-12−1,728→ 7,742 total
Exercise: $65.06Exp: 2025-06-16→ Common Stock (1,728 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-03-13−7,742→ 0 total
Exercise: $65.06Exp: 2025-06-16→ Common Stock (7,742 underlying)
Exercise/Conversion
Common Stock
2025-03-12$65.06/sh+1,728$112,424→ 351,804 total
Exercise/Conversion
Common Stock
2025-03-12$111.06/sh+6,000$666,360→ 357,804 total
Sale
Common Stock
2025-03-12$330.54/sh−1,587$524,560→ 356,217 total
Sale
Common Stock
2025-03-12$331.36/sh−2,759$914,221→ 353,458 total
Sale
Common Stock
2025-03-12$333.66/sh−800$266,926→ 350,276 total
Exercise/Conversion
Common Stock
2025-03-13$65.06/sh+7,742$503,695→ 357,818 total
Sale
Common Stock
2025-03-13$322.45/sh−1,951$629,100→ 355,867 total
Sale
Common Stock
2025-03-13$323.47/sh−1,649$533,394→ 354,218 total
Sale
Common Stock
2025-03-13$324.69/sh−900$292,218→ 353,318 total
Sale
Common Stock
2025-03-13$325.63/sh−800$260,501→ 352,518 total
Sale
Common Stock
2025-03-13$327.63/sh−1,000$327,627→ 351,518 total
Sale
Common Stock
2025-03-13$329.86/sh−967$318,975→ 350,151 total
Sale
Common Stock
2025-03-13$330.23/sh−75$24,767→ 350,076 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-03-12−6,000→ 0 total
Exercise: $111.06Exp: 2025-06-17→ Common Stock (6,000 underlying)

Holdings

Common Stock
(indirect: See Footnotes)
1,261
Common Stock
(indirect: See Footnotes)
21,000
Common Stock
(indirect: See Footnote)
11,210

Footnotes (16)

[F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.00 to $330.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
[F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $327.19 to $328.18, inclusive.
[F11]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.20 to $329.165, inclusive.
[F12]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $329.22 to $330.20, inclusive.
[F13]Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust.
[F14]These securities are held by Bay City Capital LLC ("BCC"). Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.
[F15]Represents shares held indirectly by Dr. Craves through the Craves Family Foundation.
[F16]The shares underlying this stock option are fully vested and exercisable.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $331.00 to $331.89, inclusive.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $332.01 to $332.88, inclusive.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $333.39 to $333.89, inclusive.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $334.95 to $334.99, inclusive.
[F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $322.02 to $323.00, inclusive.
[F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.02 to $323.97, inclusive.
[F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.16 to $324.84, inclusive.
[F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.34 to $325.955, inclusive.

Documents

1 file

4
wk-form4_1741983899.xmlPrimary
FORM 4

Issuer

MADRIGAL PHARMACEUTICALS, INC.

CIK 0001157601

→

Entity typeother

Related Parties

filerCIK 0001014095

Filing Metadata

Form type: 4
Filed: Mar 13, 8:00 PM ET
Accepted: Mar 14, 4:25 PM ET
Size: 37.3 KB

View on SEC.gov